Current Report Filing (8-k)
January 09 2017 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January 9, 2017
Esperion Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-35986
|
|
26-1870780
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
3891 Ranchero Drive, Suite 150
Ann Arbor, MI
|
|
48108
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(734) 887-3903
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On January 8, 2017, Esperion Therapeutics, Inc. issued a press release titled, Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid (the Phase 3 Press Release). A copy of the Phase 3 Press Release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
On January 9, 2017, Esperion Therapeutics, Inc. issued a press release titled, Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid (the CVOT Press Release). A copy of the CVOT Press Release is filed herewith as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Phase 3 Press Release dated January 8, 2017.
|
|
|
|
99.2
|
|
CVOT Press Release dated January 9, 2017.
|
* * *
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 9, 2017
|
Esperion Therapeutics, Inc.
|
|
|
|
|
By:
|
/s/ Tim M. Mayleben
|
|
|
Tim M. Mayleben
|
|
|
President and Chief Executive Officer
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Phase 3 Press Release dated January 8, 2017.
|
|
|
|
99.2
|
|
CVOT Press Release dated January 9, 2017.
|
4
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Sep 2023 to Sep 2024